Isabelle M.
- Country
- France
- Department
- ONCOLOGIE
Research Overview
- Non-Inferiority Study of Pembrolizumab Maintenance Therapy at Standard vs. Reduced Dose in Metastatic Non-Squamous Lung Cancer
- A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab
- A Phase III Double-Blind, Placebo-Controlled Study of Adjuvant Durvalumab in Resected Stage IB-IIIA Non-Small Cell Lung Cancer with PD-L1 Expression ≥25%
Data & Insights
Has run more than one trial at 179 of 460 partner sites.
Specializations
Lung Cancer Expertise
The investigator specializes in treating various forms of lung cancer, with particular emphasis on non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Their research encompasses advanced and metastatic disease states.
- EGFR-Mutated NSCLC
- Advanced Stage NSCLC
- Limited-Stage SCLC
The investigator focuses on novel therapeutic approaches including targeted therapies and immunotherapy combinations.
Mesothelioma Treatment
The investigator has significant expertise in treating malignant mesothelioma, including both pleural and peritoneal variants. Their work encompasses maintenance therapy strategies and combination treatment approaches.
- Pleural Mesothelioma
- Peritoneal Mesothelioma
- Unresectable Disease
Research interests include innovative therapeutic combinations and targeted maintenance treatments.
Immunotherapy Innovation
The investigator explores innovative applications of immunotherapy across various cancer types, with particular attention to dosing strategies and combination approaches.
- Maintenance Immunotherapy
- Combination Protocols
- Advanced Solid Tumors
Their work includes investigation of novel immunotherapy agents and optimization of treatment schedules.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.